Implementation of the N - terminal proB-type natriuretic peptide test in national guidelines for diagnosis of heart failure in Croatia
N-terminal pro B-type natriuretic peptide
Aim. In this article we aimed to analyze the implications of using new method of determination N - terminal proB - type natriuretic peptide (NT-proBNP) biomarker for rapid diagnosis in Emergency Room of acute heart failure and for prediction of adverse cardiovascular outcome.
Methods. Electro-chemiluminescence immunoassay is sandwich principle test with two monoclonal NT-proBNP-specific antibodies. PreciControl Cardiac II level 1 and level 2 with values of 150 ng/L and 4930 ng/L were analyzed by Electro-chemiluminescence immunoassay on Roche Cobas e411, in triplicate for five consecutive days in purpose for calculating within laboratory precision, according to Clinical and Laboratory Standards Institute (CLSI) protocol.
Results. According to CLSI protocol we calculated standard deviation and coefficient of variation for repeatability, intermediate precision and within laboratory precision from control results. Calculated coefficient of variation for the within laboratory precision for level 1 was 4,48% and for level 2 was 4,15%.
Conclusion. Despite very good curative cardiology, Croatia is still among the countries with high cardiovascular risks and mortality. Through the mutual dialogue and activities between leaders of Croatian Cardiac Society, Croatian Society of Hypertension and Society of Family Physicians, the consensus for the development of the Croatian Guidelines for the Diagnosis of Heart Failure (HF) has been reached.
Key words: new natriuretic peptide test, laboratory precision